Developer docs
API playgroundTry for free, no card

Search company profiles

Hyasynth Bio

Full company profile

uuid00029fm

Namestring
Hyasynth Bio
Legal namestring
Hyasynth Biologicals Inc.
Websiteurl
hyasynthbio.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Hyasynth Bio (legally Hyasynth Biologicals Inc.) is a Montreal-based biotechnology company founded in 2014 that produces pharmaceutical-grade cannabinoids via yeast fermentation rather than plant cultivation. The company has engineered proprietary yeast strains that autonomously synthesize cannabinoids as part of their natural growth cycle, requiring only standard inputs (water, sugar, air) without specialized precursors. After a controlled 3-5 day fermentation cycle monitored for temperature, acidity, growth rate, inputs, and gas outputs, the cannabinoids are separated and purified using food and pharmaceutical-grade solvents in a sterile, fully automated process. The platform is designed to scale to hundreds of thousands of litres for mass-market health product supply.

The company's product portfolio includes isolated, high-purity cannabinoids for research and product formulation, plus finished end products in pill, oil, and topical cream formats. It also offers custom cannabinoid combinations tailored for specific therapeutic applications and is pursuing rare cannabinoid discovery for future pharmaceutical products. Hyasynth operates as a Licensed Dealer under Health Canada's Narcotic Control Regulations, which permits it to produce and distribute controlled cannabinoid products only to entities authorized to possess them.

The company employs 11-50 staff and runs a B2B direct sales model in which prospective customers must register through a Typeform sales portal and disclose their regulatory authorization status. Revenue, when generated, derives from one-time sales of bulk isolated cannabinoids and custom formulations to three customer segments: cannabinoid product manufacturers (primary), research institutions, and pharmaceutical R&D clients. The company has raised approximately CAD $13.16M+ across multiple funding rounds since inception, with Organigram — a major Canadian licensed cannabis producer — serving as lead investor in the three most recent disclosed rounds (May 2018, October 2020, December 2021). Earlier backers include SOSV, Rebel Bio, Anges Québec, and the Québec government's Ministère de l'Économie et de l'Innovation.

Short descriptiontext

Hyasynth Bio is a Montreal-based biotechnology company founded in 2014 that produces pharmaceutical-grade cannabinoids through engineered yeast fermentation, supplying isolated compounds and custom formulations in pill, oil, and topical formats to authorized product manufacturers, research institutions, and pharmaceutical R&D clients under its Health Canada Licensed Dealer permit.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersMontréal, Canada
HQ citystring
Montréal
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cannabinoid biosynthesis, yeast fermentation, pharmaceutical ingredients, natural health products, biotech manufacturing
Industry1 code
PRIMARYCRADAOAI
Cultures, Probiotics & Fermentation Ingredients (Starter Cultures, Yeast, Adjuncts)
NAICS code1 code
  • Medicinal and Botanical Manufacturing325411
SIC code1 code
  • Medicinal Chemicals & Botanical Products2833
Product category
Biosynthetic Cannabinoid Manufacturing
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Bulk Cannabinoid Sales
TypeOne Time License
Description

Sale of isolated, high-quality, pure cannabinoids produced via yeast fermentation. Products can be sold as isolated compounds for research or combined into formulations.

hyasynthbio.com
2Custom Cannabinoid Formulations
TypeOne Time License
Description

Production of combinations of multiple cannabinoids formatted into pills, oils, topical creams, or other delivery formats for product manufacturers.

hyasynthbio.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Supply Chain, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Hyasynth Bio produces pure, pharmaceutical-grade cannabinoids through yeast-based biosynthesis. Specially engineered yeast strains autonomously produce cannabinoids during a 3-5 day fermentation process using only standard growth inputs (water, sugar, air). The cannabinoids are then separated, purified with food/pharmaceutical-grade solvents, and supplied as isolated compounds or formulated into pills, oils, or topical creams for authorized B2B buyers.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Hyasynth Bio is a biotechnology company that produces natural health products through yeast-based biosynthesis of cannabinoids. Their core product is isolated, pure cannabinoids produced by engineered yeast strains, which are then formulated into final consumer products including pills, oils, and topical creams. The company operates under a Licensed Dealer permit from Health Canada and focuses on producing pharmaceutical-grade cannabinoid ingredients and custom formulations for the healthcare industry. The production process spans from engineered yeast fermentation (3-5 days) through separation, purification, and formulation into final product formats.

Product and service5 records
1Isolated Cannabinoids
CategoryBiosynthetic cannabinoid ingredients
Description

Pure, high-quality cannabinoid compounds produced through engineered yeast fermentation, isolated from the fermentation mixture and purified with food and pharmaceutical-grade solvents. Sold in bulk to authorized buyers including research institutions and product manufacturers.

2Cannabinoid Pills
CategoryFinished cannabinoid dosage form
Description

Cannabinoid formulations combined into pill format for oral consumption, supplied as finished dosage units to authorized B2B customers.

3Cannabinoid Oils
CategoryFinished cannabinoid dosage form
Description

Cannabinoid formulations in oil format suitable for oral consumption or topical application, supplied to authorized B2B customers.

4Cannabinoid Topical Creams
CategoryFinished cannabinoid dosage form
Description

Cannabinoid formulations in topical cream format for external application, supplied to authorized B2B customers.

5Custom Cannabinoid Formulations
CategoryCustom cannabinoid formulation
Description

Custom combinations of multiple cannabinoids formatted into pills, oils, topical creams, or other delivery formats, tailored to specific buyer applications including pharmaceutical R&D and disease-targeted products.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Cannabis biotech focused on water-soluble cannabinoid formulations and derivative technologies. Partial overlap with Hyasynth's downstream formulation capabilities (oils, topicals) but uses different production methodology (plant-derived, not yeast-fermented).

TypeOthers
Description

Lead investor in Hyasynth and a major Canadian cannabis producer. Functions as both strategic backer and likely anchor offtake customer, with potential to internalize similar biosynthesis capabilities in-house over time.

TypeBroad incumbent
Description

Large synthetic biology platform that has partnered with Cronos Group to develop cannabinoid-producing yeast strains. Broader scope across multiple industries, but directly competing for the same cannabinoid biosynthesis opportunity with substantially greater capital and infrastructure.

TypeDirect peer
Description

Cell-based manufacturing company using engineered yeast and microorganisms to produce cannabinoids and other high-value ingredients. Direct competitor with similar B2B ingredient-supply model targeting cannabinoid formulators.

TypeEmerging player
Description

Pharmaceutical company developing cannabinoid-based prescription therapeutics, including rare cannabinoid formulations for specific disease indications. Overlaps with Hyasynth's stated interest in pharma R&D and rare cannabinoid discovery.

TypeDirect peer
Description

San Diego-based biotech using yeast and fungal fermentation to produce cannabinoids and other fungal-derived compounds. Direct overlap in core technology and product offering (isolated cannabinoids via biosynthesis).

TypeBroad incumbent
Description

Industrial synthetic biology company using yeast fermentation to produce specialty ingredients (originally terpenes, now broader ingredient portfolio). Demonstrates the production model Hyasynth employs, though Amyris operates at much larger scale and across multiple end-markets.

TypeBroad incumbent
Description

Major Canadian licensed cannabis producer that has invested in fermentation-based cannabinoid production through its partnership with Ginkgo Bioworks. Represents both a potential customer/partner and competitor with vertically integrated capabilities and significant balance sheet.

TypeDirect peer
Description

Closest comparable: yeast-based biosynthesis platform producing cannabinoids and opioid APIs. Same technology category (engineered yeast fermentation for plant-derived compounds) and same end customer base (pharma, consumer health). Highly relevant as the most-funded direct competitor in this niche.

TypeDirect peer
Description

Biotech developing proprietary yeast strains for biosynthesis of cannabinoids and other pharmaceutical compounds. Direct competitor with overlapping technology platform and target market.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds10 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Hyasynth Bio

Biosynthetic Cannabinoid Manufacturinghyasynthbio.com

Hyasynth Bio is a Montreal-based biotechnology company founded in 2014 that produces pharmaceutical-grade cannabinoids through engineered yeast fermentation, supplying isolated compounds and custom formulations in pill, oil, and topical formats to authorized product manufacturers, research institutions, and pharmaceutical R&D clients under its Health Canada Licensed Dealer permit.

What Hyasynth Bio does

Hyasynth Bio (legally Hyasynth Biologicals Inc.) is a Montreal-based biotechnology company founded in 2014 that produces pharmaceutical-grade cannabinoids via yeast fermentation rather than plant cultivation. The company has engineered proprietary yeast strains that autonomously synthesize cannabinoids as part of their natural growth cycle, requiring only standard inputs (water, sugar, air) without specialized precursors. After a controlled 3-5 day fermentation cycle monitored for temperature, acidity, growth rate, inputs, and gas outputs, the cannabinoids are separated and purified using food and pharmaceutical-grade solvents in a sterile, fully automated process. The platform is designed to scale to hundreds of thousands of litres for mass-market health product supply.

The company's product portfolio includes isolated, high-purity cannabinoids for research and product formulation, plus finished end products in pill, oil, and topical cream formats. It also offers custom cannabinoid combinations tailored for specific therapeutic applications and is pursuing rare cannabinoid discovery for future pharmaceutical products. Hyasynth operates as a Licensed Dealer under Health Canada's Narcotic Control Regulations, which permits it to produce and distribute controlled cannabinoid products only to entities authorized to possess them.

The company employs 11-50 staff and runs a B2B direct sales model in which prospective customers must register through a Typeform sales portal and disclose their regulatory authorization status. Revenue, when generated, derives from one-time sales of bulk isolated cannabinoids and custom formulations to three customer segments: cannabinoid product manufacturers (primary), research institutions, and pharmaceutical R&D clients. The company has raised approximately CAD $13.16M+ across multiple funding rounds since inception, with Organigram — a major Canadian licensed cannabis producer — serving as lead investor in the three most recent disclosed rounds (May 2018, October 2020, December 2021). Earlier backers include SOSV, Rebel Bio, Anges Québec, and the Québec government's Ministère de l'Économie et de l'Innovation.

Hyasynth Bio firmographics

Firmographics
Name
Hyasynth Bio
Legal name
Hyasynth Biologicals Inc.
Website
https://hyasynthbio.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
1–10 employees
Short description
Hyasynth Bio is a Montreal-based biotechnology company founded in 2014 that produces pharmaceutical-grade cannabinoids through engineered yeast fermentation, supplying isolated compounds and custom formulations in pill, oil, and topical formats to authorized product manufacturers, research institutions, and pharmaceutical R&D clients under its Health Canada Licensed Dealer permit.
Ownership category
akta.pro rank

Hyasynth Bio industry classification

Industry
Product category
Biosynthetic Cannabinoid Manufacturing
NAICS
Medicinal and Botanical Manufacturing (325411)
SIC
Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYCRADAOAI
Cultures, Probiotics & Fermentation Ingredients (Starter Cultures, Yeast, Adjuncts)

Keywords

  • Cannabinoid biosynthesis
  • Yeast fermentation
  • Pharmaceutical ingredients
  • Natural health products
  • Biotech manufacturing

Where Hyasynth Bio is headquartered

Location

Headquarters

HQ city
Montréal
HQ country
Canada
HQ region
North America

Offices1 record

Markets served

Hyasynth Bio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

  1. Bulk Cannabinoid Sales: Sale of isolated, high-quality, pure cannabinoids produced via yeast fermentation. Products can be sold as isolated compounds for research or combined into formulations.
  2. Custom Cannabinoid Formulations: Production of combinations of multiple cannabinoids formatted into pills, oils, topical creams, or other delivery formats for product manufacturers.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels8 records

Hyasynth Bio product offering

Product offering

Core offering

Hyasynth Bio produces pure, pharmaceutical-grade cannabinoids through yeast-based biosynthesis. Specially engineered yeast strains autonomously produce cannabinoids during a 3-5 day fermentation process using only standard growth inputs (water, sugar, air). The cannabinoids are then separated, purified with food/pharmaceutical-grade solvents, and supplied as isolated compounds or formulated into pills, oils, or topical creams for authorized B2B buyers.

Product overview

Hyasynth Bio is a biotechnology company that produces natural health products through yeast-based biosynthesis of cannabinoids. Their core product is isolated, pure cannabinoids produced by engineered yeast strains, which are then formulated into final consumer products including pills, oils, and topical creams. The company operates under a Licensed Dealer permit from Health Canada and focuses on producing pharmaceutical-grade cannabinoid ingredients and custom formulations for the healthcare industry. The production process spans from engineered yeast fermentation (3-5 days) through separation, purification, and formulation into final product formats.

Differentiator

Problem solved

Functional benefit

Products and services

  • Isolated Cannabinoids Pure, high-quality cannabinoid compounds produced through engineered yeast fermentation, isolated from the fermentation mixture and purified with food and pharmaceutical-grade solvents. Sold in bulk to authorized buyers including research institutions and product manufacturers.
  • Cannabinoid Pills Cannabinoid formulations combined into pill format for oral consumption, supplied as finished dosage units to authorized B2B customers.
  • Cannabinoid Oils Cannabinoid formulations in oil format suitable for oral consumption or topical application, supplied to authorized B2B customers.
  • Cannabinoid Topical Creams Cannabinoid formulations in topical cream format for external application, supplied to authorized B2B customers.
  • Custom Cannabinoid Formulations Custom combinations of multiple cannabinoids formatted into pills, oils, topical creams, or other delivery formats, tailored to specific buyer applications including pharmaceutical R&D and disease-targeted products.

Companies that use Hyasynth Bio

Customer profile

Segments3 records

Ideal customer profiles3 records

Hyasynth Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Hyasynth Bio partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Hyasynth Bio competitors and assessment

Company assessment

Emerging players

  • Trait Biosciences: Cannabis biotech focused on water-soluble cannabinoid formulations and derivative technologies. Partial overlap with Hyasynth's downstream formulation capabilities (oils, topicals) but uses different production methodology (plant-derived, not yeast-fermented).
  • InMed Pharmaceuticals: Pharmaceutical company developing cannabinoid-based prescription therapeutics, including rare cannabinoid formulations for specific disease indications. Overlaps with Hyasynth's stated interest in pharma R&D and rare cannabinoid discovery.

Others

  • Organigram: Lead investor in Hyasynth and a major Canadian cannabis producer. Functions as both strategic backer and likely anchor offtake customer, with potential to internalize similar biosynthesis capabilities in-house over time.

Broad incumbents

  • Ginkgo Bioworks: Large synthetic biology platform that has partnered with Cronos Group to develop cannabinoid-producing yeast strains. Broader scope across multiple industries, but directly competing for the same cannabinoid biosynthesis opportunity with substantially greater capital and infrastructure.
  • Amyris: Industrial synthetic biology company using yeast fermentation to produce specialty ingredients (originally terpenes, now broader ingredient portfolio). Demonstrates the production model Hyasynth employs, though Amyris operates at much larger scale and across multiple end-markets.
  • Cronos Group: Major Canadian licensed cannabis producer that has invested in fermentation-based cannabinoid production through its partnership with Ginkgo Bioworks. Represents both a potential customer/partner and competitor with vertically integrated capabilities and significant balance sheet.

Direct peers

  • Cellibre: Cell-based manufacturing company using engineered yeast and microorganisms to produce cannabinoids and other high-value ingredients. Direct competitor with similar B2B ingredient-supply model targeting cannabinoid formulators.
  • CB Therapeutics: San Diego-based biotech using yeast and fungal fermentation to produce cannabinoids and other fungal-derived compounds. Direct overlap in core technology and product offering (isolated cannabinoids via biosynthesis).
  • Demetrix (Antheia): Closest comparable: yeast-based biosynthesis platform producing cannabinoids and opioid APIs. Same technology category (engineered yeast fermentation for plant-derived compounds) and same end customer base (pharma, consumer health). Highly relevant as the most-funded direct competitor in this niche.
  • Biomedican: Biotech developing proprietary yeast strains for biosynthesis of cannabinoids and other pharmaceutical compounds. Direct competitor with overlapping technology platform and target market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Hyasynth Bio social profiles

Digital presence

Hyasynth Bio compliance and trust

Trust signal

Compliance1 record

Hyasynth Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Hyasynth Bio leadership team

Management profile

Number of profiles

Profiles4 records

Hyasynth Bio funding detail

Funding detail

Funding overview

Funding rounds10 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Hyasynth Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hyasynth Bio

What does Hyasynth Bio do?

Hyasynth Bio produces pure, pharmaceutical-grade cannabinoids through yeast-based biosynthesis. Specially engineered yeast strains autonomously produce cannabinoids during a 3-5 day fermentation process using only standard growth inputs (water, sugar, air). The cannabinoids are then separated, purified with food/pharmaceutical-grade solvents, and supplied as isolated compounds or formulated into pills, oils, or topical creams for authorized B2B buyers.

Is Hyasynth Bio a public or private company?

Hyasynth Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Hyasynth Bio founded?

Hyasynth Bio was founded in 2014. It employs 1 to 10 people.

Where is Hyasynth Bio based?

Hyasynth Bio is headquartered in Montréal, Canada, in the North America region.

How does Hyasynth Bio make money?

Two revenue lines are on record. Bulk Cannabinoid Sales are the primary driver. The others are custom Cannabinoid Formulations.

Who are Hyasynth Bio's main competitors?

Emerging players on record are Trait Biosciences and InMed Pharmaceuticals. Organigram is listed as an others. Broad incumbents are Ginkgo Bioworks, Amyris and Cronos Group. Direct peers are Cellibre, CB Therapeutics, Demetrix (Antheia) and Biomedican.

Does Hyasynth Bio have an API?

No public API is recorded for Hyasynth Bio.

What industry is Hyasynth Bio in?

Hyasynth Bio's product category is Biosynthetic Cannabinoid Manufacturing. Its primary akta.pro industry code is CRADAOAI, Cultures, Probiotics & Fermentation Ingredients (Starter Cultures, Yeast, Adjuncts). Its NAICS code is 325411 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Tech.euHow CBD biomanufacturing could make Europe change and win the cannabis gameCBD biomanufacturing via precision fermentation is emerging, with Europe having the most advanced infrastructure. The EU has invested over €3.7 billion in biomanufacturing, and CBD is designated a novel food. Investors and acquisitions are active, with biomanufacturing potentially overtaking traditional farming.Business InsiderHere's the 13-slide pitch deck that helped IndieBio-backed Hyasynth land a total of $10 million to produce synthetic cannabis compoundsHyasynth Biologicals raised $2.5 million in convertible debentures led by Organigram, bringing total investment to $10 million. The Montreal-based company develops synthetic cannabinoids, with analysts projecting a $115 billion market by 2040.Business Wire BlogOrganigram Makes Additional $2.5 Million Investment in Hyasynth Biologicals, a Leading Cannabinoid Biosynthesis CompanyOrganigram Holdings Inc. has acquired an additional $2.5 million in secured convertible debentures from Hyasynth Biologicals, bringing its total investment in the biotechnology firm to $10.0 million. The funds are designated to advance Hyasynth's production scalability and research into new cannabinoid technologies, including rare cannabinoids. Organigram retains board representation and a preferred partnership option to purchase Hyasynth's products at a discount upon commercial launch.PR NewswireHyasynth first to market with CBD in global race to commercialize cannabinoids produced using microbial biosynthesisHyasynth Biologicals Inc., a Montreal-based biotechnology company, has completed the first-ever commercial sale of CBD produced through yeast fermentation, making it the first company to commercialize cannabinoids via microbial biosynthesis. The company's fermentation process produces nature-identical cannabinoids in less than one week—12 times faster than traditional plant cultivation—and is pesticide and GMO-free. Hyasynth is now scaling up production to industrial volumes with plans to deliver scaled manufacturing in 2021 and is seeking additional partners to commercialize its range of bio-based cannabinoids.NanalyzeCannabis Research to Make Marijuana Cannabinoids CheaperCannabis research is developing lab-based biosynthesis of cannabinoids using yeast, bacteria, or algae, aiming to lower costs. Companies like Hyasynth and Demetrix have raised millions, and experts predict market readiness within two years. Pharmaceutical applications may become the primary use case.PR NewswireOrganigram Reports Record Net Revenue of $12.4 Million Up 287% Sequentially Quarter-over-Quarter; Adjusted Gross Margin of 71%Organigram Holdings Inc. reported record net revenue of $12.4 million for its first quarter of fiscal 2019, representing a 287% sequential increase driven by the launch of adult-use recreational cannabis sales in Canada. The company achieved an adjusted gross margin of 71% and positive free cash flow of $2.9 million, while expanding its inventory to $91.4 million and announcing strategic investments in Hyasynth Biologicals, Eviana Health Corporation, and Alpha-Cannabis Germany.PR NewswireOrganigram reports impressive growth for 2018 in advance of adult recreational sales resultsOrganigram Holdings Inc. reported fiscal year 2018 results ending August 31, 2018, with record net sales of $12.4 million (up 131% from $5.4 million in 2017), gross margin of $52.5 million, and net income of $20.5 million versus a loss of $10.9 million the prior year. The company has expanded its Moncton Campus to 52 grow rooms with targeted production capacity of 36,000 kg/yr and achieved significant cost reductions in cultivation, while completing supply agreements in nine of ten Canadian provinces ahead of the October 2018 adult recreational use market launch. Organigram also announced strategic investments totaling approximately $12.6 million in Hyasynth Biologicals, Eviana Health Corporation, and Alpha-Cannabis Germany, along with first international medical shipments to Australia.NewswireOrganigram Announces Letter of Intent for Strategic Investment in Hyasynth Biologicals Inc.Organigram Holdings entered a letter of intent to invest in Hyasynth Biologicals, proposing up to $10 million in convertible debentures and an off-take agreement. The deal would let Organigram buy up to 25% of Hyasynth's cannabinoids, with closing subject to due diligence and regulatory approval.Leafly‘Cellular Agriculture’ Could Be the Future of CannabisCellular agriculture, which uses genetic modification to produce cannabinoids like CBDV in yeast, is being developed for medical cannabis. Proponents say it is more efficient than plant farming, with medical applications such as treating epilepsy. The process is at least three to four years away from approved medical products.New ScientistMarijuana compounds made in GM yeast could help epilepsyHyasynth Bio is using genetically modified yeast to produce cannabidivarin (CBDV), a non-psychoactive marijuana compound that shows promise for treating severe epilepsy. The company aims to scale production to meet demand, as current plant-based methods are inefficient. The firm is also open to producing THC for recreational use.